FDA issues warning letter after GLP-1 manufacturer refuses inspectors access
New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.
Read the full article on the original site.
Read Full Article